Betting on Biotech
CPRIT Official Indicted for Skipping Peer Review What Is and Isn’t a Crime in Texas Guest Editorial: Reflections on FDA Warning Letter to 23andMe Bipartisan Deal Eases Some Budget Cuts By Extending Sequestration Through 2023
The House of Representatives voted 332-94 to approve a two-year budget outline Dec. 12 that would cancel $63 billion in sequester cuts for 2014 and 2015—in exchange for extending sequestration through 2023. The Bipartisan Budget Act of 2013 now heads to the Senate, where it is expected to pass next week. President Barack Obama has […]
There’s been much recent gnashing of teeth (at least within the narrow and rather insular world of do-it-yourself genomics) about the gall of the FDA in choosing to issue a warning letter to 23andMe, effectively shutting down marketing of their direct-to-consumer personal genomic profiling. And adding to 23andMe’s woes, a class action suit has been […]
A grand jury in Travis County, Texas, indicted a former official of the Cancer Prevention and Research Institute of Texas for bypassing peer review in awarding an $11 million grant to a Dallas-based company. Jerald Cobbs, the former CPRIT chief commercialization officer, was indicted on a felony charge of deceiving two of his CPRIT colleagues […]
Wall Street Analyst Who Sounded Alarm Over Prostate Cancer Drug Provenge In JNCI Settles with SEC Over Shorting Dendreon Stock An Earmark in the Making: NCI Urged to Boost Gastric Cancer Funding Johnson to Leave NCI Office of Communications FDA Expands Nexavar Indication to Include Thyroid Cancer
A group of members of both chambers of Congress is urging NCI to increase funding for research in gastric cancers—the latest in a string of advocacy initiatives to carve out fiscal support for specific diseases. “Deadly gastric cancer is on the rise in young people,” reads a Nov. 26 letter from five members of the […]
The lead author of a paper that argued that the prostate cancer immunotherapy Provenge endangered lives of cancer patients has entered a settlement agreement with the Securities and Exchange Commission. The agreement states that Marie Huber, an analyst at a hedge fund, had prepared and anonymously circulated a paper about Provenge (sipuleucel-T) at a time […]
AMY ABERNETHY was named chair of a new CancerLinQ advisory committee within the Institute for Quality, an affiliate of the American Society of Clinical Oncology.
